Medical/Pharmaceuticals Global News & Press Release Distribution

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:30 3638

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:24 3801

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-23 19:00 1652

Federal Circuit Affirms Alfred E. Mann Foundation's $268M Win Against Cochlear

Decision marks major victory for nonprofit research foundation in long-running patent dispute LOS ANGELES, March 20, 2020 /PRNewswire/ -- The U.S. Court of Appeals for the Federal Circuit has affirmed a$268 million award in favor of the Alfred E. Mann Foundation for Scientific Research (AMF) in ...

2020-03-20 05:00 2225

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

SHANGHAI, March 19, 2020 /PRNewswire/ -- Recently, scientists at Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences, together with scientists at Institute of Biophysics (IBP) of Chinese Academy of Sciences and Monash University, determined two cryo-electron microscopy (cryo...

2020-03-20 02:00 2014

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

Glooko Enables Remote Patient Care at No Charge to Medical Clinics and People with Diabetes to Minimize Risk During Pandemic

STATEMENT FROM GLOOKO RE: COVID-19 SERVICE MOUNTAIN VIEW, California, March 19, 2020 /PRNewswire/ -- Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed t...

2020-03-19 11:18 1482

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

SHANGHAI, March 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced the opening of a new, state-of-the-art,24,000 m2 laboratory facility in the Zhangjiang Hi-Tech Park inShanghai, China. The building, operating as ChemPartner's new Global Operation Center, houses approximately 700 employees ...

2020-03-17 23:07 1893

Happiness Biotech Begun Production of Daily Protective Masks

NANPING, China, March 17, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company has begun production of daily protective masks. Due to the shortage of melt-bl...

2020-03-17 20:00 6230

Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate

SONGDO, South Korea, March 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supr...

2020-03-17 08:04 1450

EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival Research Paves Way for Treatment of Drug-Resistant, End-Stage Cancers NEW YORK and SYDNEY, March 17, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its ...

2020-03-17 00:35 2037

EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells

China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales o...

2020-03-16 21:16 5055

CPHI to Hold Fiscal Year 2019 Earnings Conference Call On Tuesday March 31, 2020 at 8:30 a.m. ET

HAIKOU CITY, China, March 13, 2020 /PRNewswire/ -- China Pharmaceutical Holdings Limited (NYSE American: CPHI) ("China Pharma" or "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that it plans to hold its f...

2020-03-13 20:30 6228

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019

BEIJING, March 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2019. Fourt...

2020-03-13 05:00 10296

WuXi AppTec Wuhan Site Resumes Operation

SHANGHAI, March 11, 2020 /PRNewswire/ -- WuXi AppTec announced today that the company'sWuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at the Wuhan facility, which provides discovery chemistry services, will ramp ...

2020-03-11 20:00 1694

Concord Medical Welcomes RMB700 Million Investment

BEIJING, March 11, 2020 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research, education and prevention by operating a network of medically advanced comprehensive cancer hospitals and...

2020-03-11 15:40 5666

CIMC-produced Mobile Cabins Put Into Use in Chinese Hospitals to Help Combat Coronavirus

SHENZHEN, China, March 9, 2020 /PRNewswire/ -- The first mobile CT scan cabin produced by Yangzhou Tailee Special Equipment Co Ltd (A member enterprise of CIMC) has been put into use in a hospital in Huanggang, one of the worst hit cities by the coronavirus outbreak inHubei province, to help with...

2020-03-10 09:30 1815

CIMC-produced Mobile Cabins Put Into Use in Chinese Hospitals to Help Combat Coronavirus

NDA Filing for Luye Pharma's Antidepressant Drug LY03005 Accepted by the U.S. FDA

SHANGHAI, March. 4, 2020 /PRNewswire/ -- Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's ...

2020-03-04 21:27 2109

China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results

BEIJING, March 3, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year 2019 fi...

2020-03-03 21:30 7817

Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug

SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate. Under the agreement, Samsung Biologics will offer a wide range of services from c...

2020-03-03 03:00 1267

Yuyu Pharma announces review of compliance policies and procedures

SEOUL, South Korea, March 2, 2020 /PRNewswire/ -- Yuyu Pharma (COO Robert Wonsang Yu, KRX 000220) announced today a review of its compliance policies and procedures with the support of the law firm, Kim & Chang. The Kim & Chang project team, consisting of 6 lawyers and 1 expert advisor, implement...

2020-03-02 22:00 1229